Arcutis Biotherapeutics
Yahoo Finance • 2 months ago
Wednesday's ETF Movers: XBI, SLVR
In trading on Wednesday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 0.7% on the day. Components of that ETF showing particular strength include shares of Oruka Therapeutics, up about 5.5% and shares of Arcutis Biothera... Full story
Yahoo Finance • 2 months ago
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears
Key Points New York City-based Suvretta Capital Management increased its MLYS position by 387,641 shares in the third quarter. The overall position value increased by $57.25 million from the previous period. As of September 30, Suvretta r... Full story
Yahoo Finance • 2 months ago
This Biotech Stock Could Cure Your Portfolio's Pain
Key Points Arcutis already has its key drug approved for various diseases and concentrations. Sales are expanding rapidly, and Arcutis is positioned for growth. 10 stocks we like better than Arcutis Biotherapeutics › Investors seeking a... Full story
Yahoo Finance • 3 months ago
Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri
WESTLAKE VILLAGE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced th... Full story
Yahoo Finance • 3 months ago
These stocks are new additions to Mizuho’s ’Americas Top Picks’ list
Investing.com -- Mizuho has refreshed its monthly Americas Top Picks list, adding new high-conviction ideas selected by its U.S. equity analysts. The list highlights “our analysts’ highest conviction, catalyst-driven ideas,” Mizuho says,... Full story
Yahoo Finance • 3 months ago
Netflix target cut, Five Below target raised: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Price Target Raises: UBS raised the firm's price... Full story
Yahoo Finance • 3 months ago
FDA Accepts Arcutis' SNDA To Expand Zoryve Use To Children Aged 2-5
(RTTNews) - Commercial-stage biopharmaceutical company Arcutis Biotherapeutics, Inc. (ARQT), on Monday, said that the FDA has accepted a supplemental New Drug Application (sNDA) for Zoryve (roflumilast) cream, a once-daily, advanced target... Full story
Yahoo Finance • 3 months ago
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2 WESTLAKE VILLAGE, Ca... Full story
Yahoo Finance • 4 months ago
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the... Full story
Yahoo Finance • 4 months ago
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments
Tori Spelling shares her and her family’s journey with eczema and seborrheic dermatitis to encourage others to take control of their skin healthZORYVE® (roflumilast) is the #1 prescribed branded topical therapy for three major inflammatory... Full story
Yahoo Finance • 4 months ago
Arcutis (ARQT) Soars to Record High on Swing to Profitability, ‘More-Than-Double’ Revenues
We recently published 10 Stocks Soaring by Double Digits; Uranium Stocks Leading. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is one of the top-performing stocks on Tuesday. Arcutis jumped to a fresh record high on Tuesday, as investors ch... Full story
Yahoo Finance • 4 months ago
Noteworthy Tuesday Option Activity: CGON, DECK, ARQT
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in CG Oncology Inc (Symbol: CGON), where a total of 4,018 contracts have traded so far, representing approximately 401,800 underlying... Full story
Yahoo Finance • 4 months ago
Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results
Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and Drug Administration (FDA) approval for the... Full story
Yahoo Finance • 4 months ago
Arcutis to Present at Upcoming Investor Conferences
WESTLAKE VILLAGE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced th... Full story
Yahoo Finance • 4 months ago
Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference
New data from Phase 3 studies show once-daily ZORYVE cream helped reduce sleep disruptions in individuals with atopic dermatitis aged ≥2 yearsNew long-term data demonstrate that ZORYVE cream was well-tolerated and provided continued diseas... Full story
Yahoo Finance • 5 months ago
Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025
WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced that it will report third quarter 2025... Full story
Yahoo Finance • 5 months ago
Biotech Leader Arcutis Is Breaking Out, Up Nearly 36% in 2025
Biotech leader Arcutis stock is breaking out past its latest buy point. Shares are up nearly 36% in 2025. Continue Reading View Comments... Full story
Yahoo Finance • 5 months ago
Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress
New analysis of ZORYVE foam 0.3% demonstrates reduction in signs and symptoms of seborrheic dermatitis in individuals with diverse skin typesNew data show improved quality of life and decreased impact on families for investigational ZORYVE... Full story
Yahoo Finance • 5 months ago
ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Combines Technical Strength with High Growth Momentum
In the world of growth investing, combining technical strength with fundamental momentum often yields promising candidates. One approach gaining traction is the integration of Mark Minervini’s Trend Template with high growth momentum (HGM)... Full story
Yahoo Finance • 6 months ago
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5
If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2, offering patients and caregivers an important alternative to topical steroids and vitamin-D analogsZORYV... Full story
